LBA74Phase II study of neoadjuvant cemiplimab prior to surgery in patients with stage III/IV (M0) cutaneous squamous cell carcinoma of the head and neck (CSCC-HN)

ConclusionsNeoadjuvant cemiplimab was well-tolerated and induced a pCR or MPR in 70% of stage III/IV (M0) CSCC patients. A multicenter phase II study is planned to confirm these results and to describe the ability of neoadjuvant cemiplimab to allow less extensive treatment.Clinical trial identificationNCT03565783.Legal entity responsible for the studyThe University of Texas MD Anderson Cancer Center.FundingRegeneron.DisclosureN. Gross: Advisory / Consultancy, Research grant / Funding (self): Regeneron; Advisory / Consultancy: PDS Biotechnology; Advisory / Consultancy: Intuitive Surgical. B.S. Glisson: Research grant / Funding (institution): Pfizer; Research grant / Funding (self): ISA Pharmaceuticals. All other authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research